Archive: June 2022
Feature
Cessation of Nucleoside/Nucleotide Analogue Therapy in Chronic Hepatitis B HBeAg-Negative Patients
Abstract: Most patients treated for chronic hepatitis B infection require lifelong treatment with nucleoside/nucleotide analogues (NAs), which inhibit hepatitis B virus (HBV) replication but do not […]
Feature
Helicobacter pylori Treatment Regimens: A US Perspective
Abstract: Helicobacter pylori infects nearly one-third of the US population. H pylori is a significant cause of gastroduodenal disease, including peptic ulcers and cancers. However, rising […]
Advances in IBD
Approach to Treatment Failure in Inflammatory Bowel Disease
G&H What are the current options for conventional therapy for inflammatory bowel disease, and what are the typical response rates? AM Multiple options have been approved […]
Advances in Hepatology
Eliminating Hepatitis C Virus Infection in Indigent Patients
G&H What is the current goal for eliminating hepatitis C virus, and how close is the United States to achieving it? ET The World Health Organization […]
HCC in Focus
Exploring the Potential Chemoprophylactic Role of Carvedilol for Hepatocellular Carcinoma
G&H What are the notable risk factors for hepatocellular carcinoma? RS The main risk factor for hepatocellular carcinoma (HCC) is liver cirrhosis. A damaged liver with […]
IBS
Dietary Concerns and Patient-Focused Care in Irritable Bowel Syndrome
G&H What is known about the pathogenesis of irritable bowel syndrome? LC Irritable bowel syndrome (IBS) is now considered to be a disorder of gut-brain interaction, […]
Letter From the Editor
Managing Patients With Helicobacter pylori Infection
Helicobacter pylori infection affects more than one-half of the global population and almost one-third of the US population. Management of this infection has become more challenging […]